Table 3.
Mean number of T1 gadolinium-enhanced and active T2 lesions/patient/scan and proportion of patients with no T1 gadolinium-enhanced or active T2 lesions at the end of CLARITY Extension.
| Characteristic | CP 3.5 mg/kg (n = 98) | CP 5.25 mg/kg (n = 92) | CC 7.0 mg/kg (n = 186) | CC 8.75 mg/kg (n = 186) | PC 3.5 mg/kg (n = 244) |
|---|---|---|---|---|---|
| n (missing) | 95 (3) | 90 (2) | 178 (8) | 180 (6) | 236 (8) |
| Mean number of T1 Gd+ lesions/patient/scan, n (SD) | 0.28 (0.87) | 0.29 (1.14) | 0.03 (0.08) | 0.17 (1.04) | 0.07 (0.38) |
| Patients with no T1 Gd+ lesions, n (%) | 65 (73.0) | 65 (80.2) | 144 (88.9) | 152 (89.9) | 188 (85.1) |
| Mean number of active T2 lesions/patient/scan, n (SD) | 1.42 (3.64) | 1.44 (2.40) | 0.88 (1.63) | 1.13 (2.78) | 1.07 (1.84) |
| Patients with no active T2 lesions, n (%) | 32 (34.4) | 24 (27.6) | 64 (37.6) | 76 (43.7) | 91 (40.1) |
CC 7.0 mg/kg, cladribine 3.5 mg/kg in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg, cladribine 5.25 mg/kg in CLARITY/cladribine 3.5 mg/kg CLARITY Extension; CP 3.5 mg/kg, cladribine 3.5 mg/kg in CLARITY/placebo in CLARITY Extension; CP 5.25 mg/kg, cladribine 5.25 mg/kg in CLARITY/placebo in CLARITY Extension; PC 3.5 mg/kg, placebo in CLARITY/cladribine 3.5 mg/kg in CLARITY Extension; Gd+, gadolinium enhanced; SD, standard deviation.